Wire · opportunities
GSK catches phase 3 fever after mRNA flu vaccine beats standard shots
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 2 September 2026 · Fusion42 review
GSK's mRNA seasonal flu vaccine candidate produced higher immune responses than conventional flu shots in a phase 2 trial, prompting the company to initiate a pivotal phase 3 study. This new vaccine targets both hemagglutinin and neuraminidase, aiming to improve effectiveness over existing vaccines and capture more market share.
This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it.
◆ ◆ The Wire takeaway
You need to reposition your flu vaccine strategy as mRNA tech now pushes effectiveness expectations higher. GSK's move opens a door for improved, differentiated vaccines that demand fast trial and development adjustments.
◆ Coverage
2 sources · 1 Sep 2026
◆ Related on Wire
◆ Topics